AtaiBeckley Inc. filings document a clinical-stage biotechnology issuer with Nasdaq-listed common shares and psychiatry-focused investigational drug programs. The company’s regulatory record includes proxy and governance disclosures, shareholder voting matters, operating and financial results, clinical and regulatory updates, and risk-related information tied to development programs such as BPL-003, VLS-01, and EMP-01.
Material-event filings and registration-related documents also cover capital-structure activity, public offering agreements, resale registration matters, and acquisition-related share registration connected with Beckley Psytech. Historical filings under ATAI Life Sciences N.V. and Atai Beckley N.V. provide reference for the company’s corporate transition, financing activity, governance framework, and formal disclosure of business updates.
Morgan Stanley Smith Barney LLC Executive Financial Services filed a Rule 144 notice to sell 42,579 shares of Common Stock on 04/20/2026, described as resulting from an exercise of stock options and to be settled for cash. The filing lists the transaction as through an issuer-directed exercise.
The excerpt also discloses a prior 10b5-1 sale by Kevin James Craig of 100,000 shares on 03/20/2026 for proceeds of $355,480.00.
AtaiBeckley Inc. director and ten percent owner Christian Angermayer exercised stock options to acquire a total of 559,232 shares of common stock on April 8, 2026. The options were exercised at prices of $1.34, $1.64 and $1.88 per share.
Following these exercises, Angermayer holds 559,232 ATAI shares directly, in addition to substantial indirect holdings, including 1,799,302 shares held by Apeiron Presight Capital Fund II, L.P. and 53,412,414 shares held by Apeiron Investment Group Ltd. The filing shows option exercises only, with no reported open-market sales.